Literature DB >> 29066819

Immunotherapy: Gain beyond injection.

Diana Romero.   

Abstract

Year:  2017        PMID： 29066819     DOI： 10.1038/nrclinonc.2017.172

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Authors:  Jason Chesney; Igor Puzanov; Frances Collichio; Parminder Singh; Mohammed M Milhem; John Glaspy; Omid Hamid; Merrick Ross; Philip Friedlander; Claus Garbe; Theodore F Logan; Axel Hauschild; Celeste Lebbé; Lisa Chen; Jenny J Kim; Jennifer Gansert; Robert H I Andtbacka; Howard L Kaufman
Journal:  J Clin Oncol       Date:  2017-10-05       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.